Denali Therapeutics Announces First Patient Dosed in Phase 1b Study of DNL747 for Alzheimer’s Disease

Denali Therapeutics  (NASDAQ: DNLI) has announced the initiation of dosing in a Phase 1b clinical study of DNL747 in patients with...

Denali Therapeutics Announces First Patient Dosed in Phase 1b Study of DNL201 for Parkinson’s Disease

Denali Therapeutics (NASDAQ:DNLI), a biopharmaceutical company developing a broad portfolio of product candidates for neurodegenerative diseases, today announced initiation of dosing...

Denali Therapeutics Announces Positive Clinical Results With Its Lead RIPK1 Inhibitor Molecule

Denali Therapeutics (NASDAQ:DNLI), a biopharmaceutical company developing a broad portfolio of product candidates for neurodegenerative diseases, today announced positive results...

Denali Therapeutics Partners with Sanofi

The companies will jointly develop RIPK1 inhibitor molecules, which could treat Alzheimer’s disease, amyotrophic lateral sclerosis, multiple sclerosis and more.

Denali Therapeutics Announces Broad Collaboration with Sanofi to Develop RIPK1 Inhibitors

Denali Therapeutics (NASDAQ:DNLI), a biopharmaceutical company developing a broad portfolio of therapeutic candidates for neurodegenerative diseases, today announced that it...

CENTOGENE and Denali Therapeutics Announce Strategic Collaboration to Recruit LRRK2 Patients for Clinical Trials

CENTOGENE and Denali Therapeutics (NASDAQ:DNLI) today announced a strategic collaboration for the global identification and recruitment of LRRK2 mutation carrier...